Results 191 to 200 of about 178,854 (308)

Correction to "Pituitary Cyclase-Activating Polypeptide Targeted Treatments for the Treatment of Primary Headache Disorders". [PDF]

Ann Clin Transl Neurol
europepmc   +1 more source

Expression of melatonin receptors in trigeminal and sphenopalatine ganglia: potential targets for primary headache disorders. [PDF]

J Headache Pain
Maddahi A, Edvinsson JCA, Edvinsson L, Krause DN.   +3 more
europepmc   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl, Jonathan Grigg, Lubna Abuqayyas, Piotr Kuna, Gillian Hunter, Beata Pawlikowska, Jacob Leander, Michael Levin, Atul Gupta, James Paton, Katharine C. Pike, Jane R. Parnes, Gun Almqvist, Stephanie L. Roseti, on behalf of the study investigators   +14 more
wiley   +1 more source

Patterns of Past COVID-19 and EBV Infection in Primary Headache Disorders: A Population Study. [PDF]

Brain Behav
Pardo K, Mermelstein M, Yust-Kats S.
europepmc   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

Validation of an AI-Based platform for structured diagnosis of headache disorders using ICHD-3 criteria. [PDF]

BMC Neurol
de Andrade JBC, da Silva Costa TB, Vasconcelos JL, Lopes TLM, Balsells MD, Cristofolini VL, Querobin SO, Filho FMR.   +7 more
europepmc   +1 more source

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Balcinrenone (previously AZD9977) is a novel selective non‐steroidal mineralocorticoid receptor antagonist (MRA) with a differential mechanism of action relative to approved MRAs. The aim of this trial was to assess the pharmacokinetics, safety and tolerability of balcinrenone in participants with mild and moderate hepatic impairment ...
Anna L. Eriksson, Deeyen Karsanji, Bonifride Tuyishimire, Joanna Parkinson, Maria Heijer, Tadeusz Pawlik, Judith Hartleib‐Geschwindner, Maria Leonsson‐Zachrisson, Hans Ericsson   +8 more
wiley   +1 more source

The prevalence of headache disorders among children and adolescents in Georgia: a cross-sectional schools-based study. [PDF]

J Headache Pain
Tatishvili NN, Katsarava Z, Shatirishvili T, Kipiani T, Giuashvili T, Lomsianidze M, Kotetishvili A, Kvernadze A, Tugushi I, Maghlakelidze S, Nemsadze V, Bedoshvili A, Bitskinashvili T, Sakvarelidze G, Şaşmaz T, Erdal D, Husøy AK, Uludüz D, Steiner TJ.   +18 more
europepmc   +1 more source

Development of a nalmefene formulation suitable for a community‐use auto‐injector

British Journal of Clinical Pharmacology, EarlyView.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano, Manjunath S. Shet, Hugh Huang, Ronnie Ortiz, Garth T. Whiteside, Glen Apseloff, Stephen C. Harris   +6 more
wiley   +1 more source

The prevalence of headache disorders in children and adolescents in Nepal: a schools-based cross-sectional study. [PDF]

J Headache Pain
Ojha R, Karn R, Gajurel BP, Rajbhandari R, Gautam N, Deo B, Timilsina A, Adhikari A, Timasina RR, Nepal G, Şaşmaz T, Yalçın BNB, Berring-Uldum A, Husøy AK, Uludüz D, Steiner TJ.   +15 more
europepmc   +1 more source